RxDoctor Payments Data

David Brown, DO

Neurology · Garden Grove, CANPI 1669652533

Payments from drug & device makers

$10,376in general payments, 2019–2025

Across 427 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Novartis$960
  • UCB, Inc.$958
  • Biogen$886
  • Lilly USA, LLC$686
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$9,52092%
  • Education$7067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,376 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$56,756
Medicare patients
172
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$154,713
BotoxOnabotulinumtoxina28$38,073
RytaryCarbidopa/Levodopa23$29,705
BriviactBrivaracetam18$26,236
UbrelvyUbrogepant24$24,883
AptiomEslicarbazepine Acetate19$22,924
Nurtec OdtRimegepant Sulfate20$21,525
Aripiprazole52$15,283
Emgality PenGalcanezumab-Gnlm18$12,366
Ajovy AutoinjectorFremanezumab-Vfrm12$8,576
Aimovig AutoinjectorErenumab-Aooe11$8,100
Entacapone27$6,948
Carbidopa-LevodopaCarbidopa/Levodopa285$5,641
Levetiracetam211$5,631
Droxidopa15$4,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$1,509$62,95652 claims
Amneal Pharmaceuticals LLCRytary$324$29,70523 claims
UCB, Inc.Briviact$958$26,23618 claims
Sunovion Pharmaceuticals Inc.Aptiom$75$22,92419 claims
PfizerNurtec Odt$344$21,52520 claims
Upsher-smith Laboratories LLCTopiramate$73$1,378151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →